Tin tức & Cập nhật

Bimekizumab outperformed risankizumab in the American College of Rheumatology ≥50 percent response criteria (ACR50) among patients with active psoriatic arthritis (PsA) in the phase IIIb BE BOLD trial – the first head-to-head PsA study to demonstrate superiority for a joint-focused primary endpoint. 

Results from the GIraFFE* study shed light on the potential protective effect of whole goat milk formula (WGF) against the development of atopic dermatitis (AD) in infants, compared with cow milk formula (CF).

An investigational, immune-modulatory cancer vaccine, IO102-IO103, when combined with pembrolizumab results in sustained progression-free survival (PFS) compared with pembrolizumab alone in patients with advanced melanoma, reports a study.